|
Jun 12
|
AstraZeneca champions early kidney disease diagnosis with modelling data
|
|
Jun 11
|
Why AstraZeneca plc (NASDAQ:AZN) is Investors’ One of Favorite International Dividend Stock?
|
|
Jun 10
|
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
|
|
Jun 10
|
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
|
|
Jun 10
|
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
|
|
Jun 10
|
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
|
|
Jun 8
|
Most CEOs are defeating attempts to vote down their pay. Can Tesla's Elon Musk do the same?
|
|
Jun 7
|
The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now
|
|
Jun 7
|
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
|
|
Jun 7
|
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
|
|
Jun 6
|
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
|
|
Jun 5
|
AstraZeneca completes Fusion Pharmaceuticals acquisition
|
|
Jun 4
|
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
|
|
Jun 4
|
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
|
|
Jun 3
|
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
|
|
Jun 2
|
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
|
|
Jun 2
|
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
|
|
Jun 2
|
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
|
|
Jun 2
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
|
|
Jun 2
|
3 No-Brainer Stocks to Buy in June
|